Legacy recruits heavily to meet growing steriles demand
Company to reach 250 employees by year end to meet growing drug product manufacturing demand.
Legacy Pharmaceuticals it aims to increase headcount to 250 employees by year end to respond to the increasing demand in one-stop-shop drug products manufacturing services, as well as investing in its current assets.
Mike Danzi, Legacy CEO comments: “Being based in Basel we are fortunate to be able draw from a pool of highly educated and motivated staff - the region has in excess of 900 pharma and medtech companies employing over 50,000 people. This combination of motivation, skill and experience is key to successful project transfer success and will ensure we can support both present and future customers in their drive to succeed in the increasingly competitive biologics market.”
Legacy has been recruiting steadily during the year, enabling a move to third shifts in both semi solids and steriles, the restructuring of the engineering department, additional QA/validation/qualification resources and the expansion of the IT organisation.
“New employees tell us they value our breadth of products and the opportunities they have for further professional development. We actively encourage ownership of projects and creativity, while trying to foster a friendly supportive family environment. Because in the final analysis, spending money on new equipment and capacity means nothing if you do not have the right people to run it,” concludes Danzi.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.